Preparing a PSUR (Periodic Safety Update Report) does not have to be difficult — yet for many pharmaceutical companies, it is. Teams must analyze global safety data, track regulatory timelines, and compile complex reports while ensuring full compliance with pharmacovigilance requirements. A single mistake or delay in a periodic safety update report can lead to regulatory findings, submission delays, or increased compliance risk.

The real challenge? Preparing a PSUR requires integrating adverse event data, literature reviews, clinical findings, and benefit-risk evaluations into one structured document within strict regulatory deadlines.

That’s why many companies start searching for recommended vendors for periodic safety reports — trusted partners who can simplify periodic safety update report preparation and ensure every PSUR submission is accurate, compliant, and delivered on time.

Why companies need expert support?

Preparing a PSUR is not just a regulatory task – it is a complex pharmacovigilance process that requires deep expertise, structured data analysis, and strict compliance with global guidelines. A periodic safety update report provides regulators with a comprehensive evaluation of a medicine’s safety profile and benefit-risk balance at defined intervals after market authorization.

This is exactly why many pharmaceutical and biotech companies start searching for recommended vendors for periodic safety reports.

Creating a high-quality PSUR involves far more than just compiling adverse event data. Global safety information is analyzed, literature reviews are integrated, safety signals are evaluated, cumulative benefit-risk assessment of the product is performed. In addition, marketing authorization holders are legally required to submit these reports according to strict timelines and regulatory frameworks such as EU GVP and ICH pharmacovigilance guidelines.

For many organizations, internal resources are simply not enough to manage this workload efficiently. Pharmacovigilance teams are already responsible for case processing, signal detection, regulatory reporting, and safety monitoring. Adding the preparation of a full periodic safety update report significantly increases operational pressure.

That is why outsourcing has become a strategic solution. Companies increasingly rely on recommended vendors for periodic safety reports who can provide specialized expertise, ensure regulatory compliance, and streamline the entire PSUR preparation process, while their own PV teams remain prepared for regular pharmacovigilance activities.

In the next sections, we’ll explore what to look for when selecting the right PSUR vendor—including compliance, expertise, and technology capabilities that ensure successful periodic safety update report submissions.

What companies must do when preparing a PSUR (periodic safety update report)

Preparing a PSUR requires much more than compiling safety data, as mentioned before. A periodic safety update report is a structured pharmacovigilance document that evaluates the benefit-risk balance of a medicinal product at defined intervals after authorization.

To meet regulatory expectations, companies must follow a rigorous process aligned with global pharmacovigilance guidelines such as ICH and EU Good Pharmacovigilance Practices (GVP). These frameworks define the structure, data requirements, and evaluation approach for every periodic safety update report.

In practice, organizations must complete several critical steps:

1. Collect global safety data
Companies must gather safety information from multiple sources, including adverse event databases, clinical trials, literature monitoring, and post-marketing surveillance.

2. Perform signal evaluation and benefit-risk analysis
The PSUR requires a cumulative review of safety signals and a scientific assessment of whether the product’s benefits continue to outweigh its risks.

3. Prepare a structured regulatory report
Each periodic safety update report follows a defined format, including exposure data, safety summaries, signal evaluations, and an integrated benefit-risk assessment.

4. Meet strict submission timelines
Marketing authorization holders must submit PSURs at predefined intervals according to regulatory schedules and substance-specific submission dates.

Because this process requires specialized expertise, cross-functional coordination, and strict regulatory compliance, many companies rely on recommended vendors for periodic safety reports to ensure that every PSUR is prepared accurately and submitted on time.

How Billev East helps with PSUR (Periodic Safety Update Report) preparation

Preparing a compliant PSUR does not have to be a burden for your pharmacovigilance team. At Billev Pharma East, we support pharmaceutical companies that are searching for recommended vendors for periodic safety reports by transforming complex regulatory obligations into structured, manageable processes. As an experienced pharmacovigilance vendor, our role is not only to help prepare a periodic safety update report, but to ensure that the entire pharmacovigilance framework behind it is compliant, efficient, and inspection-ready.

Our experts work closely with marketing authorization holders to manage safety obligations throughout the product lifecycle. This includes establishing robust pharmacovigilance systems, performing ongoing benefit-risk evaluations, and preparing regulatory documents such as PSURs and risk management plans.

What makes our approach different is that we bridge the gap between regulatory requirements and real operational workflows. Instead of treating a periodic safety update report as a one-time document, we integrate PSUR preparation into a broader pharmacovigilance strategy supported by comprehensive pharmacovigilance services that ensure continuous safety monitoring and regulatory compliance. Our team combines regulatory affairs expertise, medical writing capabilities, and pharmacovigilance consulting to support companies in meeting EU and global regulatory expectations.

For companies managing multiple products, evolving regulations, and strict submission timelines, this partnership provides clarity and confidence. Rather than struggling with fragmented processes, organizations gain a trusted expert team that helps ensure every PSUR is accurate, compliant, and delivered on time — allowing internal teams to focus on innovation while we safeguard regulatory success.

Key considerations when choosing recommended vendors for PSUR (Periodic Safety Update Report)

Choosing the right partner among recommended vendors for periodic safety reports is a strategic decision for pharmaceutical and biotech companies. After all, a PSUR is not just another regulatory document — it is a core pharmacovigilance requirement used by regulators to evaluate whether a medicinal product continues to have a favorable benefit-risk balance after market authorization.

Because a periodic safety update report integrates safety data from multiple sources, its preparation requires a combination of regulatory expertise, scientific analysis, and structured pharmacovigilance processes. Companies therefore must choose vendors who can support this complexity while ensuring full regulatory compliance and operational efficiency.

One of the most important considerations is regulatory compliance. Vendors must demonstrate strong knowledge of international pharmacovigilance frameworks such as ICH guidelines and EU GVP Module VII, which define how PSURs are structured, evaluated, and submitted to health authorities.

Equally important is domain expertise. Preparing a PSUR involves analyzing adverse event data, reviewing scientific literature, evaluating safety signals, and performing a cumulative benefit-risk assessment. This requires professionals with deep pharmacovigilance experience and strong medical writing capabilities.

Finally, companies should evaluate the vendor’s technology and service capabilities. Efficient data management systems, structured workflows, and scalable pharmacovigilance services help ensure that each periodic safety update report is prepared accurately and submitted on time.

When these elements come together — compliance, expertise, and technology —  organizations gain a reliable partner who can support consistent and high-quality PSUR submissions.

What is a PSUR (Periodic Safety Update Report) and why it matters

A PSUR (Periodic Safety Update Report)is a key pharmacovigilance document submitted by pharmaceutical companies to regulatory authorities at defined intervals after a medicine has been approved. Its purpose is to provide a comprehensive and critical evaluation of the product’s safety profile and benefit-risk balance over time.

Unlike individual adverse event reports, a periodic safety update report offers a cumulative perspective. It integrates safety information from multiple sources, including adverse event databases, clinical trials, scientific literature, and post-marketing surveillance data.

Regulatory authorities review these reports to determine whether new safety signals have emerged or whether the overall benefit-risk balance of the medicine has changed. If necessary, PSUR assessments may lead to regulatory actions such as updates to product information, additional risk minimization measures, or further safety investigations.

For pharmaceutical companies, this makes the PSUR one of the most critical ongoing compliance obligations after market authorization. Preparing a high-quality periodic safety update report ensures that regulators have a clear understanding of the medicine’s safety profile and helps maintain trust in the product’s continued use.

What is important when preparing a Periodic Safety Update Report (PSUR)

Preparing a periodic safety update report requires a structured and well-coordinated pharmacovigilance process. The goal of a PSUR is to present a complete overview of a medicine’s safety experience and evaluate whether its benefits continue to outweigh its risks.

This process begins with collecting and integrating global safety data from a variety of sources. The collected data must then be carefully analyzed to identify potential safety signals and evaluate any new or emerging risks associated with the product.

Another important aspect is the scientific interpretation of safety data. Preparing a PSUR is not only about summarizing information but also about performing a cumulative benefit-risk evaluation that reflects the current knowledge about the product. This assessment helps regulators understand whether additional safety measures may be required.

Equally critical areregulatory timelines and reporting standards. Companies must follow strict submission schedules and prepare their reports according to established pharmacovigilance guidelines such as ICH and EU GVP. Missing deadlines or submitting incomplete reports can lead to regulatory scrutiny or compliance issues.

Because of these requirements, the preparation of a PSUR has become one of the most demanding pharmacovigilance activities. Many organizations therefore rely on specialized partners who can ensure that every periodic safety update report meets regulatory expectations while maintaining high scientific and quality standards.

Ensuring successful PSUR (Periodic Safety Update Report) submissions

A well-prepared PSUR plays a crucial role in pharmacovigilance because it provides regulators with an updated evaluation of a medicine’s safety profile and benefit–risk balance after market authorization.

For pharmaceutical companies, preparing a compliant periodic safety update report requires scientific analysis, regulatory expertise, and strict adherence to submission timelines. By working with experienced partners and structured pharmacovigilance processes, organizations can ensure that each PSUR submission is accurate, compliant, and supports long-term patient safety and regulatory trust.

Read also:

• Pharmacovigilance services that help you meet the new EU expectations
• How does signal detection integrate with overall signal management in post-market drug safety?
• How is a pharmacovigilance system master file structured according to EU regulatory requirements?

Sources: Sources: 1 – European Medicines Agency. (n.d.). Periodic safety update reports (PSURs), 2 – European Medicines Agency. (n.d.). Periodic safety update report (PSUR) – glossary, 3 – European Medicines Agency. (2013). Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report, 4 – Italian Medicines Agency (AIFA). (n.d.). PSUR – Periodic safety update reports, 5 – Medicines Evaluation Board (CBG-MEB). (n.d.). Periodic safety update reports (PSUR), 6 – Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). (n.d.). Periodic safety update reports (PSURs), 7 – International Council for Harmonisation. (n.d.). ICH E2C – Clinical safety data management: Periodic safety update reports.

Image credits:

In-article images: Designed by Freepik

Hero image: Designed by Freepik